Showing results (441-450 of 554) with videos related to
Sort By:
Pageof 56
World Journal of Urology|September 8, 2018
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatmentC Leigh Moyer, Ryan Phillips, Matthew P Deek, et al.JCO Precision Oncology|June 21, 2019
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate TumorsJon H Chung, Ninad Dewal, Ethan Sokol, et al.European Urology Oncology|June 16, 2020
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerMatthew P Deek, Kekoa Taparra, Ryan Phillips, et al.JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.Cell Reports. Medicine|April 21, 2026
Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patientsAli T Arafa, Ella Boytim, Megan L Ludwig, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or EnzalutamideKatherine A Zukotynski, Urban Emmenegger, Sebastien Hotte, et al.BMC Cancer|July 1, 2017
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Noura Radwan, Ryan Phillips, Ashley Ross, et al.International Journal of Molecular Sciences|June 26, 2025
HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial CancersNikitha Vobugari, Allison Makovec, Samuel Kellen, et al.British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.Proceedings of the National Academy of Sciences of the United States of America|May 31, 2018
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13Zhong Chen, Dayong Wu, Jennifer M Thomas-Ahner, et al.Pageof 56